

James Larkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/272595/publications.pdf>

Version: 2024-02-01

168
papers

64,134
citations

18482

62
h-index

8396

147
g-index

172
all docs

172
docs citations

172
times ranked

51666
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Predictive biomarkers for response to immune checkpoint inhibition. <i>Seminars in Cancer Biology</i> , 2022, 79, 4-17. | 9.6 | 70 |
| 2 | Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137. | 1.6 | 446 |
| 3 | Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 17-25. | 2.4 | 7 |
| 4 | Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1068-1080. | 1.6 | 43 |
| 5 | Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results >2,000 patients in 41 countries, with focus on older patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, 306-306. | 1.6 | 1 |
| 6 | External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 1772-1782. | 1.6 | 9 |
| 7 | Reply to T. Olivier et al. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200209. | 1.6 | 0 |
| 8 | Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1929-1938. | 1.6 | 33 |
| 9 | Prognostic and predictive value of I^2 -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2022, 165, 97-112. | 2.8 | 18 |
| 10 | Spatial patterns of tumour growth impact clonal diversification in a computational model and the TRACERx Renal study. <i>Nature Ecology and Evolution</i> , 2022, 6, 88-102. | 7.8 | 30 |
| 11 | Frequency of pathogenic germline variants in cancer susceptibility genes in 1336 renal cell carcinoma cases. <i>Human Molecular Genetics</i> , 2022, 31, 3001-3011. | 2.9 | 9 |
| 12 | Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. <i>Cancers</i> , 2022, 14, 2300. | 3.7 | 6 |
| 13 | Abstract A012: Advanced melanoma exhibits a diversity of evolutionary routes to lethality. <i>Cancer Research</i> , 2022, 82, A012-A012. | 0.9 | 0 |
| 14 | Abstract PR002: Advanced melanoma exhibits a diversity of evolutionary routes to lethality. <i>Cancer Research</i> , 2022, 82, PR002-PR002. | 0.9 | 0 |
| 15 | Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9522-9522. | 1.6 | 37 |
| 16 | CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA4503-LBA4503. | 1.6 | 3 |
| 17 | EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48. | 0.9 | 153 |
| 18 | Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2021, 124, 237-246. | 6.4 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options. <i>Cells</i> , 2021, 10, 327. | 4.1 | 37 |
| 20 | The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. <i>Melanoma Research</i> , 2021, 31, 181-185. | 1.2 | 14 |
| 21 | Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. <i>Cell</i> , 2021, 184, 596-614.e14. | 28.9 | 485 |
| 22 | Reply to E. Hindi. <i>Journal of Clinical Oncology</i> , 2021, 39, 944-946. | 1.6 | 1 |
| 23 | Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1020-1028. | 1.6 | 83 |
| 24 | CACtUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS9587-TPS9587. | 1.6 | 8 |
| 25 | Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 655-664. | 10.7 | 37 |
| 26 | Association of health-related quality of life (HRQoL) and treatment safety with nivolumab (NIVO) in patients (pts) with resected stage IIIB/C or IV melanoma: Analysis of CheckMate 238 four-year follow-up (FU) data. <i>Journal of Clinical Oncology</i> , 2021, 39, 9574-9574. | 1.6 | 5 |
| 27 | Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). <i>Journal of Clinical Oncology</i> , 2021, 39, 4547-4547. | 1.6 | 0 |
| 28 | Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy. <i>Journal of Clinical Oncology</i> , 2021, 39, 9505-9505. | 1.6 | 10 |
| 29 | Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from the 2020 Global Patient Survey from 41 countries. <i>Journal of Clinical Oncology</i> , 2021, 39, 4579-4579. | 1.6 | 0 |
| 30 | Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238. <i>Journal of Clinical Oncology</i> , 2021, 39, 9569-9569. | 1.6 | 4 |
| 31 | Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654. | 10.7 | 224 |
| 32 | 5-Year Outcomes with Cobimetinib plus Vemurafenib in <i>BRAF</i> V600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. <i>Clinical Cancer Research</i> , 2021, 27, 5225-5235. | 7.0 | 82 |
| 33 | Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis. <i>Lancet Oncology</i> , The, 2021, 22, 905-907. | 10.7 | 2 |
| 34 | Abstract CT004: Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915). <i>Cancer Research</i> , 2021, 81, CT004-CT004. | 0.9 | 28 |
| 35 | Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. <i>Journal of Clinical Oncology</i> , 2021, 39, e002742. | | 16 |
| 36 | Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis. <i>Journal of Hepatology</i> , 2021, 75, 177-189. | 3.7 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Severe progressive scarring pembrolizumab-induced lichen planopilaris in a patient with metastatic melanoma. <i>Australasian Journal of Dermatology</i> , 2021, 62, 403-406. | 0.7 | 3 |
| 38 | Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2656-2666. | 1.6 | 145 |
| 39 | TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma. <i>Cancer Immunology Research</i> , 2021, 9, 1202-1213. | 3.4 | 71 |
| 40 | RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. <i>Contemporary Clinical Trials</i> , 2021, 108, 106481. | 1.8 | 2 |
| 41 | RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. <i>Contemporary Clinical Trials</i> , 2021, 108, 106482. | 1.8 | 33 |
| 42 | Isolated imbalance due to bilateral vestibular failure following immune checkpoint inhibitor administration: two cases. <i>European Journal of Cancer</i> , 2021, 156, 187-189. | 2.8 | 2 |
| 43 | Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 1497-1518.e11. | 16.8 | 126 |
| 44 | Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. , 2021, 9, e003743. | | 14 |
| 45 | Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2021, 158, 156-168. | 2.8 | 19 |
| 46 | Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. <i>European Urology Focus</i> , 2020, 6, 999-1005. | 3.1 | 5 |
| 47 | An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 561-570. | 2.2 | 43 |
| 48 | Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo. <i>JAMA Oncology</i> , 2020, 6, 519. | 7.1 | 287 |
| 49 | Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4064-4075. | 1.6 | 78 |
| 50 | Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. <i>Cancer</i> , 2020, 126, 4156-4167. | 4.1 | 201 |
| 51 | Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design. <i>Future Oncology</i> , 2020, 16, 2165-2175. | 2.4 | 20 |
| 52 | Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. <i>Nature Communications</i> , 2020, 11, 3800. | 12.8 | 61 |
| 53 | Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000852. | 4.5 | 18 |
| 54 | Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. <i>New England Journal of Medicine</i> , 2020, 383, 1139-1148. | 27.0 | 256 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Adjuvant nivolumab versus ipilimumab in resected stage IIIB&C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1465-1477. | 10.7 | 330 |
| 56 | Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3925-3936. | 1.6 | 192 |
| 57 | Metastatic melanoma: therapeutic agents in preclinical and early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 739-753. | 4.1 | 2 |
| 58 | British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 679-697. | 8.1 | 33 |
| 59 | Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. <i>Clinical Cancer Research</i> , 2020, 26, 4201-4205. | 7.0 | 30 |
| 60 | Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. <i>Cell Reports</i> , 2020, 31, 107550. | 6.4 | 51 |
| 61 | Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020, 130, 126-138. | 2.8 | 84 |
| 62 | Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 343-354. | 2.4 | 0 |
| 63 | Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389. | 10.7 | 155 |
| 64 | Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 1535-1546. | 27.0 | 2,484 |
| 65 | Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600E/K mutant advanced or metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 109, 61-69. | 2.8 | 63 |
| 66 | Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. <i>European Journal of Cancer</i> , 2019, 116, 207-215. | 2.8 | 35 |
| 67 | Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. <i>European Journal of Cancer</i> , 2019, 116, 148-157. | 2.8 | 64 |
| 68 | Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with <i>BRAF</i>V600-mutated Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 3239-3246. | 7.0 | 32 |
| 69 | Reply to E. Hindi© and K.R. Hess. <i>Journal of Clinical Oncology</i> , 2019, 37, 1356-1358. | 1.6 | 1 |
| 70 | Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1103-1115. | 27.0 | 1,824 |
| 71 | OP0165&...EULAR RECOMMENDATIONS FOR THE DIAGNOSIS AND THE MANAGEMENT OF RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS DUE TO CANCER IMMUNOTHERAPY. , 2019, , . | | 0 |
| 72 | PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. <i>BMC Cancer</i> , 2019, 19, 1102. | 2.6 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. New England Journal of Medicine, 2018, 378, 1789-1801. | 27.0 | 1,441 |
| 74 | Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal. Cell, 2018, 173, 581-594.e12. | 28.9 | 609 |
| 75 | BMI and outcomes in melanoma: more evidence for the obesity paradox. Lancet Oncology, The, 2018, 19, 269-270. | 10.7 | 14 |
| 76 | Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. European Journal of Cancer, 2018, 91, 168-170. | 2.8 | 33 |
| 77 | Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigatorâ€™s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Journal of Clinical Oncology, 2018, 36, 383-390. | 1.6 | 431 |
| 78 | Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600â€“Mutant Stage III Melanoma. Journal of Clinical Oncology, 2018, 36, 3441-3449. | 1.6 | 226 |
| 79 | PTU-009â€“Upper gastrointestinal inflammation in patients with immune-checkpoint inhibitor induced diarrhoea. , 2018, , . | | 2 |
| 80 | PWE-025â€“Microscopic colonic inflammation in immune check point inhibitor-induced diarrhoea/colitis. , 2018, , . | | 1 |
| 81 | Elevated Levels of <i>BRAF</i> ^{V600} Mutant Circulating Tumor DNA and Circulating Hepatocyte Growth Factor Are Associated With Poor Prognosis in Patients With Metastatic Melanoma. JCO Precision Oncology, 2018, 2, 1-17. | 3.0 | 3 |
| 82 | Effects of Molecular Heterogeneity on Survival of Patients With BRAFV600-Mutated Melanoma Treated With Vemurafenib With or Without Cobimetinib in the coBRIM Study. JCO Precision Oncology, 2018, 2, 1-18. | 3.0 | 4 |
| 83 | Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 1480-1492. | 10.7 | 1,089 |
| 84 | Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncology, The, 2018, 19, e447-e458. | 10.7 | 376 |
| 85 | Adjuvant Vascular Endothelial Growth Factorâ€“targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. European Urology, 2018, 74, 611-620. | 1.9 | 77 |
| 86 | Modeled Prognostic Subgroups for Survival and Treatment Outcomes in <i>BRAF</i> V600â€“Mutated Metastatic Melanoma. JAMA Oncology, 2018, 4, 1382. | 7.1 | 65 |
| 87 | Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877742. | 3.2 | 7 |
| 88 | Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. Journal of Clinical Oncology, 2017, 35, 226-235. | 1.6 | 458 |
| 89 | Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. Expert Review of Clinical Pharmacology, 2017, 10, 1-12. | 3.1 | 3 |
| 90 | Renal cell carcinoma. Nature Reviews Disease Primers, 2017, 3, 17009. | 30.5 | 1,727 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study. <i>European Journal of Cancer</i> , 2017, 80, 55-62. | 2.8 | 18 |
| 92 | Genome-wide association study identifies multiple risk loci for renal cell carcinoma. <i>Nature Communications</i> , 2017, 8, 15724. | 12.8 | 106 |
| 93 | Gene Expression Profiling in <i>BRAF</i> -Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib. <i>Clinical Cancer Research</i> , 2017, 23, 5238-5245. | 7.0 | 32 |
| 94 | Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 647-655. | 2.4 | 14 |
| 95 | Reply to "Comment on "Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy". <i>British Journal of Cancer</i> , 2017, 116, e15-e15. | 6.4 | 1 |
| 96 | Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 785-792. | 1.6 | 930 |
| 97 | Survival of patients with advanced metastatic melanoma: the impact of novel therapies"update 2017. <i>European Journal of Cancer</i> , 2017, 83, 247-257. | 2.8 | 236 |
| 98 | Adjuvant Dabrafenib plus Trametinib in Stage III <i>BRAF</i> -Mutated Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1813-1823. | 27.0 | 1,192 |
| 99 | Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835. | 27.0 | 1,752 |
| 100 | Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356. | 27.0 | 3,589 |
| 101 | PNFLBA-16 FIRST RESULTS OF A-PREDICT: A PHASE II STUDY OF AXITINIB IN PATIENTS WITH METASTATIC RENAL CELL CANCER (RCC) UNSUITABLE FOR NEPHRECTOMY. <i>Journal of Urology</i> , 2017, 197, . | 0.4 | 0 |
| 102 | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet, The</i> , 2017, 390, 1853-1862. | 13.7 | 1,032 |
| 103 | Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. <i>Lancet Oncology, The</i> , 2017, 18, 1009-1021. | 10.7 | 716 |
| 104 | Contrast-Enhanced CT Density Predicts Response to Sunitinib Therapy in Metastatic Renal Cell Carcinoma Patients. <i>Translational Oncology</i> , 2017, 10, 679-685. | 3.7 | 9 |
| 105 | The safety of nivolumab for the treatment of metastatic melanoma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 955-961. | 2.4 | 7 |
| 106 | Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2017, 3, 1511. | 7.1 | 131 |
| 107 | Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017, 82, 80-91. | 2.8 | 76 |
| 108 | Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered. <i>European Urology</i> , 2017, 71, 845-847. | 1.9 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 109 | Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?. Melanoma Management, 2017, 4, 151-155. | 0.5 | 2 |
| 110 | Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. Journal of Clinical Oncology, 2017, 35, 3807-3814. | 1.6 | 364 |
| 111 | Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncology, The, 2016, 17, 1248-1260. | 10.7 | 832 |
| 112 | The combination of vemurafenib and cobimetinib in advanced melanoma. Expert Opinion on Orphan Drugs, 2016, 4, 1105-1111. | 0.8 | 3 |
| 113 | Recent developments in melanoma management. Trends in Urology & Men's Health, 2016, 7, 8-12. | 0.4 | 0 |
| 114 | Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. Lancet Oncology, The, 2016, 17, e4-e5. | 10.7 | 103 |
| 115 | Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. Expert Opinion on Biological Therapy, 2016, 16, 389-396. | 3.1 | 35 |
| 116 | Extrinsic factors can mediate resistance to <scp>BRAF</scp> inhibition in central nervous system melanoma metastases. Pigment Cell and Melanoma Research, 2016, 29, 92-100. | 3.3 | 44 |
| 117 | Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. Journal of the National Cancer Institute, 2016, 108, djv414. | 6.3 | 81 |
| 118 | Survival of patients with advanced metastatic melanoma: The impact of novel therapies. European Journal of Cancer, 2016, 53, 125-134. | 2.8 | 137 |
| 119 | Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 167.e17-167.e23. | 1.6 | 22 |
| 120 | A Phase 1 first-in-human trial to evaluate the safety and tolerability of CCT3833, an oral panRAF inhibitor, in patients with advanced solid tumours, including metastatic melanoma.. Journal of Clinical Oncology, 2016, 34, TPS9597-TPS9597. | 1.6 | 2 |
| 121 | Pembrolizumab in the management of metastatic melanoma. Melanoma Management, 2015, 2, 315-325. | 0.5 | 4 |
| 122 | Pazopanib-Induced Alopecia, an Underestimated Toxicity?. Frontiers in Oncology, 2015, 5, 112. | 2.8 | 4 |
| 123 | Sunitinib in Metastatic Renal Cell Carcinoma: A Systematic Review of UK Real World Data. Frontiers in Oncology, 2015, 5, 195. | 2.8 | 5 |
| 124 | Challenging the Treatment Paradigm for Advanced Renal Cell Carcinoma: A Review of Systemic and Localized Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e239-e247. | 3.8 | 9 |
| 125 | Carbonic anhydrase IX in resected clear cell RCC. Nature Reviews Urology, 2015, 12, 309-310. | 3.8 | 5 |
| 126 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 2015, 373, 23-34. | 27.0 | 6,773 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 127 | Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 444-451. | 13.7 | 1,175 |
| 128 | Prognostic score for patients with advanced melanoma treated with ipilimumab. <i>European Journal of Cancer</i> , 2015, 51, 2785-2791. | 2.8 | 53 |
| 129 | SnapShot: Renal Cell Carcinoma. <i>Cell</i> , 2015, 163, 1556-1556.e1. | 28.9 | 50 |
| 130 | Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. <i>Lancet Oncology</i> , The, 2015, 16, 1473-1482. | 10.7 | 762 |
| 131 | PACMEL: A phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel. <i>European Journal of Cancer</i> , 2015, 51, 359-366. | 2.8 | 21 |
| 132 | Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology</i> , The, 2015, 16, 15-17. | 10.7 | 10 |
| 133 | Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction. <i>Cancer Cell</i> , 2015, 27, 240-256. | 16.8 | 299 |
| 134 | Translational Implications of Tumor Heterogeneity. <i>Clinical Cancer Research</i> , 2015, 21, 1258-1266. | 7.0 | 424 |
| 135 | Efficacy and Safety of Nivolumab in Patients With <i>BRAF</i> V600 Mutant and <i>BRAF</i> Wild-Type Advanced Melanoma. <i>JAMA Oncology</i> , 2015, 1, 433. | 7.1 | 201 |
| 136 | Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840. | 2.8 | 71 |
| 137 | Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2521-2532. | 27.0 | 4,838 |
| 138 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 375-384. | 10.7 | 2,353 |
| 139 | Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. <i>Nature Communications</i> , 2015, 6, 6336. | 12.8 | 100 |
| 140 | Intravital Imaging Reveals How BRAF Inhibition Generates Drug-Tolerant Microenvironments with High Integrin $\beta 1$ /FAK Signaling. <i>Cancer Cell</i> , 2015, 27, 574-588. | 16.8 | 485 |
| 141 | Relapse models for clear cell renal carcinoma. <i>Lancet Oncology</i> , The, 2015, 16, e376-e378. | 10.7 | 3 |
| 142 | Abstract CT101: Phase III study of pembrolizumab (MK-3475) versus ipilimumab in patients with ipilimumab-naïve advanced melanoma. , 2015, , . | | 2 |
| 143 | Common Variation at 1q24.1 (ALDH9A1) Is a Potential Risk Factor for Renal Cancer. <i>PLoS ONE</i> , 2015, 10, e0122589. | 2.5 | 19 |
| 144 | High-risk cutaneous melanoma follow-up: time for more intensive surveillance?. <i>Melanoma Management</i> , 2014, 1, 7-10. | 0.5 | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 145 | Systematic Evaluation of the Prognostic Impact and Intratumour Heterogeneity of Clear Cell Renal Cell Carcinoma Biomarkers. <i>European Urology</i> , 2014, 66, 936-948. | 1.9 | 141 |
| 146 | Axitinib for the Treatment of Metastatic Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 397-403. | 1.3 | 23 |
| 147 | Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. <i>Nature Genetics</i> , 2014, 46, 225-233. | 21.4 | 1,103 |
| 148 | Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1867-1876. | 27.0 | 1,824 |
| 149 | Systemic anti-cancer therapy (SACT) dataset. <i>Lancet Oncology</i> , The, 2014, 15, 1063. | 10.7 | 3 |
| 150 | Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888. | 27.0 | 1,572 |
| 151 | Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology</i> , The, 2014, 15, 323-332. | 10.7 | 890 |
| 152 | Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. <i>Lancet Oncology</i> , The, 2014, 15, 436-444. | 10.7 | 242 |
| 153 | Advances in immunotherapy for melanoma. <i>Melanoma Management</i> , 2014, 1, 19-24. | 0.5 | 0 |
| 154 | Abstract 1192: Establishment and characterization of a new patient-derived renal cell carcinoma xenograft panel. , 2014, , . | | 0 |
| 155 | Individualising treatment choices in a crowded treatment algorithm. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 160-168. | 2.2 | 2 |
| 156 | Common variation at 2q22.3 (ZEB2) influences the risk of renal cancer. <i>Human Molecular Genetics</i> , 2013, 22, 825-831. | 2.9 | 54 |
| 157 | Abstract LB-144: Modeling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance.. , 2013, , . | | 1 |
| 158 | Abstract 4603: Intratumor heterogeneity in clear cell renal cell carcinoma (ccRCC): Multi-region sequencing redefines the mutational landscape of ccRCCs.. <i>Cancer Research</i> , 2013, 73, 4603-4603. | 0.9 | 1 |
| 159 | Abstract 3404: Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.. , 2013, , . | | 0 |
| 160 | Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. <i>New England Journal of Medicine</i> , 2012, 366, 883-892. | 27.0 | 6,769 |
| 161 | Epigenetic regulation in RCC: opportunities for therapeutic intervention?. <i>Nature Reviews Urology</i> , 2012, 9, 147-155. | 3.8 | 51 |
| 162 | Abstract 964: Intra-tumor heterogeneity and Darwinian selection revealed by multi-region exome sequencing of renal cell carcinomas. , 2012, , . | | 1 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 163 | Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma. Anticancer Research, 2012, 32, 2399-406. | 1.1 | 9 |
| 164 | Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. New England Journal of Medicine, 2011, 364, 2507-2516. | 27.0 | 6,976 |
| 165 | Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Review of Anticancer Therapy, 2011, 11, 639-649. | 2.4 | 14 |
| 166 | Is advanced renal cell carcinoma becoming a chronic disease?. Lancet, The, 2010, 376, 574-575. | 13.7 | 11 |
| 167 | Advances in the Management of Metastatic Renal Cell Cancer. European Urology Supplements, 2009, 8, 758-761. | 0.1 | 0 |
| 168 | Malignant melanoma (metastatic). Clinical Evidence, 2008, 2008, . | 0.2 | 0 |